ORLANDO, FL, USA (UroToday.com) - This study investigated the addition of bevacizumab to the standard regimen of cisplatin/gemcitabine as first-line therapy for patients with metastatic urothelial carcinoma (UC).
Your session will expire in 8 hours requiring you to log in each day to view content.